Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background: Definitive concurrent chemoradiotherapy (dCRT) is standard for locally advanced esophageal squamous cell carcinoma (ESCC), but recurrences remain common. Evidence for consolidation immunotherapy after dCRT is limited. This study evaluated the efficacy and safety of consolidation immunotherapy after dCRT and explored the association between programmed death-ligand 1 (PD-L1) expression and treatment outcomes.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
